<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004755</url>
  </required_header>
  <id_info>
    <org_study_id>199/11679</org_study_id>
    <secondary_id>HSPH-11679</secondary_id>
    <nct_id>NCT00004755</nct_id>
  </id_info>
  <brief_title>Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil</brief_title>
  <official_title>Phase II Randomized Study of Allopurinol Versus Glucantime Versus Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard School of Public Health (HSPH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVE:&#xD;
&#xD;
      Compare the efficacy and side effects of allopurinol versus glucantime versus&#xD;
      allopurinol/glucantime in patients in Brazil with cutaneous leishmaniasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      This is a randomized study. Patients are stratified by participating institution.&#xD;
&#xD;
      One group is treated with daily intramuscular injections of glucantime. Patients with less&#xD;
      than a complete response on Day 21 continue treatment until lesions heal completely or for a&#xD;
      maximum of 60 days. Patients with progressive disease on Day 40 are removed from study.&#xD;
&#xD;
      The second group is treated with daily oral allopurinol. Patients with a partial response on&#xD;
      Day 21 continue treatment until lesions heal completely. Patients with stable or progressive&#xD;
      disease on Day 21 or unhealed lesions on Day 56 cross to glucantime therapy. Accrual into&#xD;
      this group was closed in 6/96.&#xD;
&#xD;
      The third group receives allopurinol and glucantime.&#xD;
&#xD;
      Patients are followed at 3, 6, and 9 months, then annually for at least 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1995</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>375</enrollment>
  <condition>Leishmaniasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allopurinol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucantime</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Parasitologically confirmed cutaneous leishmaniasis (lesion of less than 3 months duration)&#xD;
&#xD;
        No mucocutaneous leishmaniasis&#xD;
&#xD;
        No prior leishmaniasis&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        No prior treatment for leishmaniasis&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Hepatic: No clinical or laboratory evidence of hepatic disease&#xD;
&#xD;
        Renal: No clinical or laboratory evidence of renal disease No hyperuricemia or gout&#xD;
&#xD;
        Cardiovascular: No clinical, electrocardiographic, or laboratory evidence of cardiac&#xD;
        disease&#xD;
&#xD;
        Other: No allergy or other contraindication to allopurinol or glucantime; No concurrent&#xD;
        medication that might interact with study drugs, e.g.: probenecid, warfarin, azathioprine;&#xD;
        No skin rash; No malnutrition; No other medical contraindication to protocol therapy; No&#xD;
        pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James H. Maguire</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard School of Public Health (HSPH)</affiliation>
  </overall_official>
  <verification_date>January 1998</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>dermatologic disorders</keyword>
  <keyword>environmental/toxic disorders</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>leishmaniasis</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meglumine Antimoniate</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

